Archivos y Bases de datos

In [1]:

    

import mysql.connector


    

In [2]:

    

import pandas as pd
df= pd.read_csv('C:/Users/Alex/Documents/eafit/semestres/X semestre/programacion/taller2.tsv', sep = '\t')
df[:1]


    

    




C:\Users\Alex\Anaconda3\lib\site-packages\IPython\core\interactiveshell.py:2717: DtypeWarning: Columns (12,23,27) have mixed types. Specify dtype option on import or set low_memory=False.
  interactivity=interactivity, compiler=compiler, result=result)






    
Out[2]:






  

    

      

      
DATE ADDED TO CATALOG
      
PUBMEDID
      
FIRST AUTHOR
      
DATE
      
JOURNAL
      
LINK
      
STUDY
      
DISEASE/TRAIT
      
INITIAL SAMPLE SIZE
      
REPLICATION SAMPLE SIZE
      
...
      
CONTEXT
      
INTERGENIC
      
RISK ALLELE FREQUENCY
      
P-VALUE
      
PVALUE_MLOG
      
P-VALUE (TEXT)
      
OR or BETA
      
95% CI (TEXT)
      
PLATFORM [SNPS PASSING QC]
      
CNV
    
  
  

    

      
0
      
2009-09-28
      
18403759
      
Ober C
      
2008-04-09
      
N Engl J Med
      
www.ncbi.nlm.nih.gov/pubmed/18403759
      
Effect of variation in CHI3L1 on serum YKL-40 ...
      
YKL-40 levels
      
632 Hutterite individuals
      
443 European ancestry cases, 491 European ance...
      
...
      
upstream_gene_variant
      
0.0
      
0.29
      
1e-13
      
13.0
      
NaN
      
0.3
      
[NR] ng/ml decrease
      
Affymetrix [290325]
      
N
    
  

1 rows × 34 columns

In [5]:

    

CREATE TABLE enfermedad
(
id_enfermedad int PRIMARY KEY,
nombre varchar(255)
);

create table plataforma
(
id_plataforma int primary key, 
nombre varchar(255)
);

CREATE TABLE loci
(
id_loci int NOT NULL PRIMARY KEY,
region varchar(255),
chrom varchar(255), 
pos int,
genes_reportados int,
gen_mapped varchar(255),
gen_upstream int,
gen_downstream int,
SNP_GENE_IDS int,
UPSTREAM_GENE_DISTANCE int,
DOWNSTREAM_GENE_DISTANCE int,
STRONGEST_SP_RISK varchar(255),
SNPS varchar(255),
MERGED int,
SNP_ID_CURRENT varchar(255),
CONTEXTO varchar(255),
risk_allele varchar(255),
PVAl int,
PVALUE_MLOG int,
PVALUE_txt varchar(255),
BETA int,  
novCI varchar(255),
id_plataforma int,
foreign key (id_plataforma) references plataforma(id_plataforma)
);

CREATE TABLE enfermedad_loci
(
id_enfermedad int,
id_loci int,
PRIMARY KEY (id_enfermedad, id_loci),
foreign key (id_enfermedad) references enfermedad(id_enfermedad),
foreign key (id_loci) references loci(id_loci)
);

CREATE TABLE journal
(
id_journal int primary key,
nombre varchar(255)
);

create table publicacion
(
id_publicacion int,
id_pubmed int,
autor varchar (255),
fecha_pub varchar (20),
link varchar (255),
id_journal int,
id_estudio int,
foreign key (id_journal) references journal(id_journal),
foreign key (id_estudio) references estudio(id_estudio)
);

CREATE TABLE estudio
(
nombre varchar(255),
id_estudio int primary key,
id_enfermedad int,
id_publicacion int,
foreign key (id_publicacion) references publicacion(id_publicacion),
foreign key (id_enfermedad) references enfermedad(id_enfermedad),
tamano_muestra int,
replicas int
);


    

    




  File "<ipython-input-5-d1b77f55e9ba>", line 1
    CREATE TABLE enfermedad
               ^
SyntaxError: invalid syntax

In [6]:

    

df.head(1)


    

    
Out[6]:






  

    

      

      
DATE ADDED TO CATALOG
      
PUBMEDID
      
FIRST AUTHOR
      
DATE
      
JOURNAL
      
LINK
      
STUDY
      
DISEASE/TRAIT
      
INITIAL SAMPLE SIZE
      
REPLICATION SAMPLE SIZE
      
...
      
CONTEXT
      
INTERGENIC
      
RISK ALLELE FREQUENCY
      
P-VALUE
      
PVALUE_MLOG
      
P-VALUE (TEXT)
      
OR or BETA
      
95% CI (TEXT)
      
PLATFORM [SNPS PASSING QC]
      
CNV
    
  
  

    

      
0
      
2009-09-28
      
18403759
      
Ober C
      
2008-04-09
      
N Engl J Med
      
www.ncbi.nlm.nih.gov/pubmed/18403759
      
Effect of variation in CHI3L1 on serum YKL-40 ...
      
YKL-40 levels
      
632 Hutterite individuals
      
443 European ancestry cases, 491 European ance...
      
...
      
upstream_gene_variant
      
0.0
      
0.29
      
1e-13
      
13.0
      
NaN
      
0.3
      
[NR] ng/ml decrease
      
Affymetrix [290325]
      
N
    
  

1 rows × 34 columns

In [6]:

    

hostname = '127.0.0.1'
username = 'alexacl95'
password = 'SUSAna05'
database = 'programacion'

def doQuery( conn ) :
    cur = conn.cursor()

    cur.execute( "select * from enfermedad" )

    for id_nombre, nombre_enf in cur.fetchall() :
        print (id_nombre, nombre_enf)

myConnection = mysql.connector.connect( host=hostname, user=username, passwd=password, db=database )
doQuery( myConnection )
myConnection.close()


    

    




1 YKL-40 levels
2 Psoriasis
3 Lung cancer
4 Nicotine dependence
5 Colorectal cancer
6 Type 2 diabetes
7 Breast cancer
8 Schizophrenia
9 Urate levels
10 Celiac disease
11 Prostate cancer
12 LDL cholesterol
13 Fetal hemoglobin levels
14 Recombination rate (females)
15 Recombination rate (males)
16 Iris color
17 Systemic lupus erythematosus
18 Type 1 diabetes
19 HDL cholesterol
20 Triglycerides
21 Height
22 Amyotrophic lateral sclerosis
23 Coronary spasm
24 Rheumatoid arthritis
25 Blond vs. brown hair color
26 Blue vs. green eyes
27 Freckles
28 Skin pigmentation
29 Select biomarker traits
30 Body mass index
31 Waist circumference
32 Sleep-related phenotypes
33 Cystatin C
34 Thyroid stimulating hormone
35 Urinary albumin excretion
36 Bone mineral density
37 Hip geometry
38 Atrial fibrillation
39 Heart failure
40 Major CVD
41 Blood pressure
42 Tonometry
43 Morbidity-free survival
44 Aging traits
45 Diabetes related insulin traits
46 Fasting plasma glucose
47 Diabetes (incident)
48 Electrocardiographic traits
49 Heart rate variability traits
50 Coronary artery calcification
51 Subclinical atherosclerosis traits (other)
52 Cognitive test performance
53 Volumetric brain MRI
54 Echocardiographic traits
55 Endothelial function traits
56 Exercise treadmill test traits
57 Mean forced vital capacity from 2 exams
58 Pulmonary function
59 Factor VII
60 Hemostatic factors and hematological phenotypes
61 Crohn's disease
62 F-cell distribution
63 Glaucoma (exfoliation)
64 Type 2 diabetes nephropathy
65 Neuroticism
66 Multiple sclerosis
67 Asthma
68 Obesity-related traits
69 Restless legs syndrome
70 Coronary heart disease
71 Gallstones
72 Atrial fibrillation/atrial flutter
73 Bipolar disorder
74 Hypertension
75 Stroke
76 Myocardial infarction
77 Age-related macular degeneration (wet)
78 Parkinson's disease
79 QT interval
80 Age-related macular degeneration
81 C-reactive protein
82 Alzheimer's disease (late onset)
83 Melanoma
84 Black vs. blond hair color
85 Protein quantitative trait loci
86 Neuroblastoma
87 Knee osteoarthritis
88 Waist circumference and related phenotypes
89 Bone mineral density (spine)
90 Black vs. red hair color
91 Bone mineral density (hip)
92 Response to iloperidone treatment (QT prolongation)
93 Warfarin maintenance dose
94 Red vs. non-red hair color
95 Burning and freckling
96 End-stage renal disease
97 Skin sensitivity to sun
98 Osteonecrosis of the jaw
99 Arthritis (juvenile idiopathic)
100 Soluble ICAM-1
101 Response to TNF antagonist treatment
102 Crohn's disease and sarcoidosis (combined)
103 Response to diuretic therapy
104 Chronic lymphocytic leukemia
105 IgE levels
106 Inflammatory bowel disease
107 Vitamin B12 levels
108 Obesity (early onset extreme)
109 Alzheimer's disease
110 Red vs non-red hair color
111 Blue vs. brown eyes
112 Response to statin therapy
113 Urinary bladder cancer
114 Narcolepsy
115 Hip bone size
116 Uric acid levels
117 Attention deficit hyperactivity disorder
118 Ulcerative colitis
119 Male-pattern baldness
120 Basal cell carcinoma
121 Idiopathic pulmonary fibrosis
122 Liver enzyme levels
123 Intracranial aneurysm
124 Brain imaging in schizophrenia (interaction)
125 Stroke (ischemic)
126 Personality dimensions
127 Parkinson's disease (familial)
128 Attention deficit hyperactivity disorder and conduct disorder
129 Attention deficit hyperactivity disorder symptoms (interaction)
130 Cholesterol, total
131 Metabolite levels
132 Conduct disorder (interaction)
133 Metabolic traits
134 Multiple sclerosis (age of onset)
135 Multiple sclerosis (severity)
136 Normalized brain volume
137 Brain lesion load
138 Iron status biomarkers
139 Mean platelet volume
140 AIDS progression
141 Kawasaki disease
142 Lp (a) levels
143 Major depressive disorder
144 Creutzfeldt-Jakob disease
145 Adiponectin levels
146 Response to treatment for acute lymphoblastic leukemia
147 Essential tremor
148 Asthma (toluene diisocyanate-induced)
149 Pain
150 Panic disorder
151 Hirschsprung disease
152 Thyroid cancer
153 Eosinophil counts
154 Myocardial infarction (early onset)
155 Carotenoid and tocopherol levels
156 Otosclerosis
157 Body mass (lean)
158 Biochemical measures
159 Anthropometric traits
160 Orofacial clefts
161 Venous thromboembolism
162 Chronic obstructive pulmonary disease
163 Folate pathway vitamin levels
164 Myeloproliferative neoplasms
165 Anti-cyclic Citrullinated Peptide Antibody
166 Tanning
167 Atopic dermatitis
168 Hepatitis B
169 Telomere length
170 Aging
171 Biomedical quantitative traits
172 Hyperactive-impulsive symptoms
173 Inattentive symptoms
174 Attention deficit hyperactivity disorder (time to onset)
175 Electrocardiographic conduction measures
176 Neuroblastoma (high-risk)
177 Autism
178 Bilirubin levels
179 Systolic blood pressure
180 Diastolic blood pressure
181 Hypertension (young onset)
182 Renal function and chronic kidney disease
183 Menarche (age at onset)
184 Malaria
185 Menarche and menopause (age at onset)
186 Testicular cancer
187 Testicular germ cell tumor
188 Nasopharyngeal carcinoma
189 Left ventricular mass
190 Glycated hemoglobin levels
191 Drug-induced liver injury (flucloxacillin)
192 Male infertility
193 Quantitative traits
194 Kidney stones
195 Adiposity
196 Obesity (extreme)
197 Glioma
198 Glioma (high-grade)
199 Cutaneous nevi
200 Alcohol dependence
201 Acenocoumarol maintenance dosage
202 Follicular lymphoma
203 Pancreatic cancer
204 Cardiac structure and function
205 Aortic root size
206 Ovarian cancer
207 Bladder cancer
208 Response to antipsychotic treatment
209 Response to hepatitis C treatment
210 Acute lymphoblastic leukemia (childhood)
211 Esophageal cancer
212 Hippocampal atrophy
213 Asthma (childhood onset)
214 Type 2 diabetes and other traits
215 Obesity and osteoporosis
216 Soluble E-selectin levels
217 Exercise (leisure time)
218 AIDS
219 Myopia (pathological)
220 Speech perception in dyslexia
221 Hemoglobin
222 Hematological parameters
223 IFN-related cytopenia
224 Fibrinogen
225 Systemic sclerosis
226 Hepatitis B vaccine response
227 Interstitial lung disease
228 Vascular endothelial growth factor levels
229 Cardiovascular disease risk factors
230 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
231 Hepcidin levels
232 Aging (time to death)
233 Phospholipid levels (plasma)
234 Aging (time to event)
235 Epirubicin-induced leukopenia
236 Meningioma
237 Nevirapine-induced rash
238 vWF and FVIII levels
239 Type 1 diabetes autoantibodies
240 Cortical thickness
241 Tardive dyskinesia
242 Iris characteristics
243 Graves' disease
244 Response to metformin
245 Butyrylcholinesterase levels
246 Osteoarthritis
247 Insulin resistance/response
248 Non-small cell lung cancer
249 Proinsulin levels
250 Coffee consumption
251 Coronary restenosis
252 Retinol levels
253 HPV seropositivity
254 Aspartate aminotransferase
255 Permanent tooth development
256 Gamma glutamyl transpeptidase
257 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
258 Thoracic aortic aneurysms and dissections
259 Carotid intima media thickness
260 Dental caries
261 Corneal structure
262 Testosterone levels
263 Response to antipsychotic therapy (extrapyramidal side effects)
264 Cytomegalovirus antibody response
265 Lipoprotein-associated phospholipase A2 activity and mass
266 Dengue shock syndrome
267 Smoking behavior
268 Renal cell carcinoma
269 Premature ovarian failure
270 Response to platinum-based agents
271 Leprosy
272 Scoliosis
273 Lipid traits
274 Liver enzyme levels (alanine transaminase)
275 Liver enzyme levels (alkaline phosphatase)
276 Liver enzyme levels (gamma-glutamyl transferase)
277 Gastric cancer
278 Renal sinus fat
279 White blood cell count
280 Cognitive decline
281 Abdominal aortic aneurysm
282 Response to anti-depressant treatment in major depressive disorder
283 Aortic stiffness
284 Allergic rhinitis
285 IgE grass sensitization
286 Gamma gluatamyl transferase levels
287 Femoral neck bone geometry
288 Depression and alcohol dependence
289 Hypothyroidism
290 Epilepsy
291 Multiple myeloma
292 Cognitive function
293 Corneal astigmatism
294 Endometriosis
295 Conduct disorder (symptom count)
296 Conduct disorder
297 Hair color
298 Behcet's disease
299 Eye color
300 Freckling
301 Common traits (Other)
302 Primary biliary cirrhosis
303 Nephropathy
304 Peripheral artery disease
305 Lumiracoxib-related liver injury
306 Resting heart rate
307 Alopecia areata
308 Phosphorus levels
309 Ribavirin-induced anemia
310 Hematology traits
311 Hepatocellular carcinoma
312 Glomerulosclerosis
313 Tuberculosis
314 Meningococcal disease
315 Immunoglobulin A
316 Keloid
317 Neonatal lupus
318 Emphysema-related traits
319 Metabolic syndrome
320 Calcium levels
321 CD4:CD8 lymphocyte ratio
322 Magnesium levels
323 Chronic kidney disease and serum creatinine levels
324 Self-rated health
325 Schizophrenia, bipolar disorder and depression (combined)
326 Hypertriglyceridemia
327 Esophageal cancer and gastric cancer
328 Central corneal thickness
329 Migraine
330 Bitter taste response
331 Lung adenocarcinoma
332 Refractive error
333 Non-alcoholic fatty liver disease histology (other)
334 Non-alcoholic fatty liver disease histology (lobular)
335 Non-alcoholic fatty liver disease histology (AST)
336 Multiple sclerosis--Brain Glutamate Levels
337 Protein C levels
338 Glaucoma (primary open-angle)
339 Depression (quantitative trait)
340 Smoking cessation
341 Fuchs's corneal dystrophy
342 Adverse response to aromatase inhibitors
343 Red blood cell traits
344 Suicidal ideation
345 Antipsychotic-induced QTc interval prolongation
346 Waist-hip ratio
347 Erectile dysfunction and prostate cancer treatment
348 Psoriatic arthritis
349 Cerebrospinal AB1-42 levels
350 Cerebrospinal T-tau levels
351 Cerebrospinal P-tau181p levels
352 Body mass in chronic obstructive pulmonary disease
353 Radiation response
354 Dupuytren's disease
355 Suicide risk
356 Hodgkin's lymphoma
357 Breast cancer in BRCA2 mutation carriers
358 Retinal vascular caliber
359 Moyamoya disease
360 Non-small cell lung cancer (survival)
361 Event-related brain oscillations
362 Atrioventricular conduction
363 Bipolar disorder and schizophrenia
364 QRS duration
365 Handedness in dyslexia
366 Anorexia nervosa
367 HIV-1 control
368 Weight
369 Hypospadias
370 Small-cell lung cancer (survival)
371 Response to antipsychotic treatment in schizophrenia (working memory)
372 Response to antipsychotic treatment in schizophrenia (reasoning)
373 Response to bleomycin (chromatid breaks)
374 Amyloid A serum levels
375 Primary sclerosing cholangitis
376 Ileal carcinoids
377 Polycystic ovary syndrome
378 Adverse response to carbamapezine
379 Asperger disorder
380 Response to acetaminophen (hepatotoxicity)
381 Hoarding
382 Alzheimer's disease biomarkers
383 Progranulin levels
384 Bone mineral density (wrist)
385 Response to metformin in type 2 diabetes (glycemic)
386 HIV-1 susceptibility
387 N-glycan levels
388 Serum prostate-specific antigen levels
389 Information processing speed
390 HIV-1 progression
391 Chronic hepatitis C infection
392 Adolescent idiopathic scoliosis
393 Cardiac muscle measurement
394 Insulin-like growth factors
395 Thyroid cancer (Papillary, radiation-related)
396 Asparaginase hypersensitivity in acute lymphoblastic leukemia
397 Coronary artery disease
398 Percent mammographic density
399 Response to anti-TNF alpha therapy in inflammatory bowel disease
400 Crohn's disease and celiac disease
401 C-reactive protein levels
402 Optic disc area
403 Natriuretic peptide levels
404 Diabetic retinopathy
405 PR interval
406 HIV-1 replication
407 Vitiligo
408 Metabolic syndrome (bivariate traits)
409 HDL Cholesterol - Triglycerides (HDLC-TG)
410 Triglycerides-Blood Pressure (TG-BP)
411 Waist Circumference - Triglycerides (WC-TG)
412 Personality traits in bipolar disorder
413 Celiac disease or Rheumatoid arthritis
414 Drinking behavior
415 Cerivastatin-induced rhabdomyolysis
416 Cardiac hypertrophy
417 Alcohol consumption
418 Bipolar disorder (age of onset and psychotic symptoms)
419 Nonalcoholic fatty liver disease
420 Suicide attempts in bipolar disorder
421 Vaccine-related adverse events
422 Nephrotic syndrome (acquired)
423 Upper aerodigestive tract cancers
424 Idiopathic membranous nephropathy
425 5-HTT brain serotonin transporter levels
426 Uterine fibroids
427 Large B-cell lymphoma
428 Neuranatomic and neurocognitive phenotypes
429 Endometrial cancer
430 Caffeine consumption
431 Response to interferon beta therapy
432 Response to platinum-based chemotherapy in non-small-cell lung cancer
433 Caudate nucleus volume
434 Dilated cardiomyopathy
435 D-dimer levels
436 Neutrophil count
437 Platelet count
438 Glaucoma
439 Dehydroepiandrosterone sulphate levels
440 Longevity
441 Attention deficit hyperactivity disorder motor coordination
442 Alcoholism (heaviness of drinking)
443 Alcoholism (alcohol use disorder factor score)
444 Alcoholism (alcohol dependence factor score)
445 Alcoholism (12-month weekly alcohol consumption)
446 Monocyte early outgrowth colony forming units
447 Obesity
448 Urinary metabolites
449 Chronic myeloid leukemia
450 Dialysis-related mortality
451 Thyroid volume
452 Drug-induced liver injury (amoxicillin-clavulanate)
453 Osteoporosis
454 Cystic fibrosis severity
455 Platelet function and related traits
456 Paget's disease
457 Response to antineoplastic agents
458 Alcohol consumption (transferrin glycosylation)
459 Corneal curvature
460 White matter hyperintensity burden
461 Sudden cardiac arrest
462 Progressive supranuclear palsy
463 Age at smoking initiation in chronic obstructive pulmonary disease
464 Cannabis dependence
465 Ulcerative colitis or Crohn's disease
466 Erythrocyte sedimentation rate
467 White blood cell types
468 Vitamin E levels
469 Ankylosing spondylitis
470 Response to gemcitabine in pancreatic cancer
471 Ovarian reserve
472 Creutzfeldt-Jakob disease (variant)
473 HIV-1 viral setpoint
474 Response to tamoxifen in breast cancer
475 IgA nephropathy
476 Prion diseases
477 Non-obstructive azoospermia
478 Ankle-brachial index
479 Substance dependence
480 Anticoagulant levels
481 Life threatening arrhythmia
482 Diabetes (gestational)
483 Inflammatory biomarkers
484 Menopause (age at onset)
485 Breast cancer (survival)
486 Lymphocyte counts
487 Lipid metabolism phenotypes
488 Infantile hypertrophic pyloric stenosis
489 Gallbladder cancer
490 Hypertension risk in short sleep duration
491 Ewing sarcoma
492 Cardiac repolarization
493 Cortical structure (interaction)
494 Facial morphology
495 Treatment response for severe sepsis
496 Temperament (bipolar disorder)
497 Response to statins (LDL cholesterol change)
498 Nephrolithiasis
499 Gaucher disease severity
500 Duodenal ulcer
501 Haptoglobin levels
502 Adverse response to lamotrigine and phenytoin
503 Thyrotoxic hypokalemic periodic paralysis
504 Sphingolipid levels
505 Body mass index and cholesterol (psychopharmacological treatment)
506 White matter integrity
507 Intelligence
508 Pulmonary function decline
509 Sexual dysfunction (SSRI/SNRI-related)
510 Schizophrenia (treatment resistant)
511 Chronic kidney disease
512 Brachial circumference
513 Glioblastoma
514 Lipid levels in hepatitis C treatment
515 Alcohol and nictotine co-dependence
516 Response to Vitamin E supplementation
517 Sexual dysfunction (female)
518 Circulating cell-free DNA
519 Head circumference (infant)
520 Brain structure
521 Intracranial volume
522 Hippocampal volume
523 Thyroid function
524 Response to tocilizumab in rheumatoid arthritis
525 Crohn's disease and psoriasis
526 Non-albumin protein levels
527 Intraocular pressure
528 Electroencephalographic traits in alcoholism
529 Response to TNF-alpha inhibitors in rheumatoid arthritis
530 HIV-associated dementia
531 Antipsychotic drug-induced weight gain
532 Response to angiotensin II receptor blocker therapy
533 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
534 Pericardial fat
535 Immune response to smallpox vaccine (IL-6)
536 Response to antidepressants
537 Coronary heart disease event reduction in response to statin therapy (interaction)
538 Immune response to anthrax vaccine
539 Parkinson's disease (motor and cognition)
540 Formal thought disorder in schizophrenia
541 Response to irinotecan in non-small-cell lung cancer
542 IgG levels
543 Other erythrocyte phenotypes
544 Hematocrit
545 Mean corpuscular hemoglobin
546 Mean corpuscular volume
547 Response to citalopram treatment
548 Iron levels
549 Homocysteine levels
550 Arterial stiffness
551 RR interval (heart rate)
552 Matrix metalloproteinase levels
553 Inflammatory bowel disease (early onset)
554 Periodontitis
555 Beta thalassemia/hemoglobin E disease
556 Atopy
557 Carotid atherosclerosis in HIV infection
558 Major depressive disorder (broad)
559 Cholesterol
560 Hearing impairment
561 Major mood disorders
562 Angiotensin-converting enzyme activity
563 Brain imaging
564 Fasting glucose-related traits
565 Fasting insulin-related traits
566 Two-hour glucose challenge
567 Response to clopidogrel therapy
568 Interleukin-18 levels
569 E-selectin levels
570 Soluble levels of adhesion molecules
571 Soluble leptin receptor levels
572 Osteoporosis-related phenotypes
573 Eosinophilic esophagitis (pediatric)
574 Functional MRI
575 C4b binding protein levels
576 Digit length ratio
577 Activated partial thromboplastin time
578 Chemerin levels
579 Birth weight
580 Creatinine levels
581 Bipolar I disorder
582 Mortality in heart failure
583 Optic nerve measurement (disc area)
584 Vitamin D levels
585 Cleft lip
586 Optic nerve measurement (cup area)
587 Optic nerve measurement (rim area)
588 Biliary atresia
589 Eye color traits
590 Platelet aggregation
591 Partial epilepsies
592 Phytosterol levels
593 End-stage renal disease (non-diabetic)
594 Testicular germ cell cancer
595 Vitamin D insufficiency
596 Optic disc parameters
597 Vertical cup-disc ratio
598 Cholelithiasis-related traits in sickle cell anemia
599 Lung cancer (asbestos exposure interaction)
600 Wilms tumor
601 Sex hormone-binding globulin levels
602 Estradiol levels
603 Erectile dysfunction in type 1 diabetes
604 Hepatitis B (viral clearance)
605 Lean body mass and age at menarche (combined)
606 Fasting insulin-related traits (interaction with BMI)
607 Fasting glucose-related traits (interaction with BMI)
608 Immune reponse to smallpox (secreted IL-2)
609 Immune reponse to smallpox (secreted IL-1beta)
610 Immune reponse to smallpox (secreted IFN-alpha)
611 Immune reponse to smallpox (secreted IL-10)
612 Immune reponse to smallpox (secreted TNF-alpha)
613 Immune reponse to smallpox (secreted IL-12p40)
614 Economic and political preferences
615 Economic and political preferences (environmentalism)
616 Economic and political preferences (fairness)
617 Economic and political preferences (feminism/equality)
618 Economic and political preferences (immigration/crime)
619 Economic and political preferences (time)
620 Breast size
621 Insomnia (caffeine-induced)
622 Temperament
623 Age-related macular degeneration (CNV)
624 Age-related macular degeneration (CNV vs. GA)
625 Age-related macular degeneration (GA)
626 Subcutaneous adipose tissue
627 Visceral fat
628 Visceral adipose tissue/subcutaneous adipose tissue ratio
629 Visceral adipose tissue adjusted for BMI
630 Prothrombin time
631 Insulin-related traits
632 C-reactive protein and white blood cell count
633 Antineutrophil cytoplasmic antibody-associated vasculitis
634 Sclerosing cholangitis and ulcerative colitis (combined)
635 Gambling
636 Renal function-related traits (BUN)
637 Cannabis use (initiation)
638 Resistin levels
639 Hepatitis C induced liver fibrosis
640 IgA levels
641 Asthma (bronchodilator response)
642 Response to fenofibrate
643 Renal function-related traits (sCR)
644 Renal function-related traits (eGRFcrea)
645 Renal function-related traits (urea)
646 Tourette syndrome
647 Obsessive-compulsive disorder
648 Capecitabine sensitivity
649 Lentiform nucleus volume
650 Airflow obstruction
651 Eating disorders
652 Sarcoidosis
653 P wave duration
654 PR segment
655 Pulse pressure in young-onset hypertension
656 Prostate cancer (early onset)
657 Response to radiotherapy in cancer (late toxicity)
658 Response to inhaled corticosteroid treatment in asthma (change in FEV1)
659 Free thyroxine concentration
660 Thyroid peroxidase antibody positivity
661 Morphine dose requirement in tonsillectomy and adenoidectomy surgery
662 Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
663 Irritable bowel syndrome
664 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
665 Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
666 Prostate-specific antigen levels
667 Immune response to measles-mumps-rubella vaccine
668 Acne (severe)
669 Forced vital capacity
670 Lupus nephritis in systemic lupus erythematosus
671 Exfoliation glaucoma or exfoliation syndrome
672 Asthma (sex interaction)
673 Chronic hepatitis B infection
674 Arsenic metabolism
675 Birdshot chorioretinopathy
676 Blood pressure (anthropometric measures interaction)
677 Bone mineral density (paediatric, total body less head)
678 Bone mineral density (paediatric, lower limb)
679 Bone mineral density (paediatric, upper limb)
680 Suicide attempts in depression or bipolar disorder
681 Neuropathic pain in type 2 diabetes
682 Response to radiotherapy in prostate cancer (toxicity)
683 Frontotemporal dementia
684 Blood metabolite levels
685 Blood metabolite ratios
686 Response to haloperidol in psychosis
687 Forced expiratory volume in 1 second
688 Chronic periodontitis
689 Local histogram emphysema pattern
690 Bone mineral density (paediatric, skull)
691 Age-related nuclear cataracts
692 Eosinophilic esophagitis
693 Age-related hearing impairment
694 Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
695 Serum lipase activity
696 Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
697 Blood pressure (age interaction)
698 Asthma or chronic obstructive pulmonary disease
699 Osteoarthritis biomarkers
700 Elevated serum carcinoembryonic antigen levels
701 Hearing function
702 Alcohol dependence (age at onset)
703 Ossification of the posterior longitudinal ligament of the spine
704 Osteoprotegerin levels
705 Suicidal ideation in depression or bipolar disorder
706 Food antigen IgG levels
707 Pneumoconiosis in silica exposure
708 Glaucoma (high intraocular pressure)
709 Serum ferritin levels
710 Hemoglobin A2 levels in sickle cell anemia
711 Tourette's syndrome or obsessive-compulsive disorder
712 Height adjusted BMI
713 Allergic rhinitis in asthma
714 Allergic rhinitis in non-asthmatics
715 Heschl's gyrus morphology
716 Vogt-Koyanagi-Harada syndrome
717 Carotid plaque burden (smoking interaction)
718 Esophageal squamous cell carcinoma
719 Congenital left-sided heart lesions
720 Epithelial ovarian cancer
721 Antinuclear antibody levels
722 Vitamin B levels in ischemic stroke
723 Amyotrophic lateral sclerosis or frontotemporal dementia
724 Creatine kinase in statin users
725 Laryngeal squamous cell carcinoma
726 Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
727 Pulmonary function in asthmatics
728 Aggressive periodontitis (sex interaction)
729 Binge eating behaviour and bipolar disorder
730 Binge eating behaviour in bipolar disorder
731 Blood pressure (smoking interaction)
732 Plasma plasminogen levels
733 Diffuse large B cell lymphoma
734 Birth length
735 Medication adherence in chronic diseases
736 Autism spectrum disorder-related traits
737 Hip circumference (psychosocial stress interaction)
738 Hepatic lipid content in extreme obesity
739 High serum lipase activity
740 Hypersomnia (HLA-DQB1*06:02 negative)
741 Psychosis (methamphetamine induced)
742 Hematological and biochemical traits
743 Circulating myeloperoxidase levels (plasma)
744 Circulating myeloperoxidase levels (serum)
745 Callous-unemotional behaviour
746 Attention deficit hyperactivity disorder (combined symptoms)
747 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
748 Attention deficit hyperactivity disorder (inattention symptoms)
749 Sensory disturbances after bilateral sagittal split ramus osteotomy
750 Weight loss (gastric bypass surgery)
751 Dietary macronutrient intake
752 PCA3 expression level
753 Brugada syndrome
754 Body mass index in asthmatics
755 Preeclampsia
756 Brain cytoarchitecture
757 Body mass index in non-asthmatics
758 Brain structure (temporal lobe volume)
759 Brain structure (hippocampal volume)
760 Crohn's disease (time to surgery)
761 Allergic dermatitis (nickel)
762 Odorant perception (β-damascenone)
763 Molar-incisor hypomineralization
764 Myopia (severe)
765 Axial length
766 IgE levels in asthmatics
767 IgE levels in asthmatics (D.p. specific)
768 IgE levels in asthmatics (D.f. specific)
769 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
770 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
771 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
772 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
773 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
774 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
775 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
776 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
777 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
778 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
779 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
780 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
781 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
782 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
783 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
784 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
785 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
786 Bitter taste perception
787 Cocaine dependence
788 Post-traumatic stress disorder (asjusted for relatedness)
789 Age-related macular degeneration (smoking status interaction)
790 Epilepsy (remission after treatment)
791 Otitis media (chronic/recurrent)
792 Blood trace element (Cu levels)
793 Blood trace element (Zn levels)
794 Blood trace element (Se levels)
795 Congenital heart disease
796 Dermatomyositis
797 Borderline personality disorder features
798 Cardiovascular heart disease in diabetics
799 Airway hyperresponsiveness
800 Osteoarthritis (hip)
801 Acute lymphoblastic leukemia (B-cell precursor)
802 Response to mTOR inhibitor (rapamycin)
803 Response to mTOR inhibitor (everolimus)
804 Orthostatic hypotension
805 Sleep time
806 Sleep quality
807 Sleep depth
808 Sleep duration
809 Insomnia
810 Educational attainment
811 Serum protein levels (sST2)
812 Adolescent idiopathic scoliosis (severe)
813 Response to diuretic therapy in hypertension
814 Nicotine use
815 Illicit drug use
816 Non-substance related behavioral disinhibition
817 Mesial temporal lobe epilepsy with hippocampal sclerosis
818 Wegener's granulomatosis
819 Reading and spelling
820 Adverse response to chemotherapy in breast cancer (alopecia)
821 Systemic lupus erythematosus and Systemic sclerosis
822 Non-word repetition
823 Word reading
824 End-stage renal disease in Type 1 diabetics
825 Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
826 Systolic blood pressure in sickle cell anemia
827 Social communication problems
828 Hormone measurements
829 Fat body mass
830 Gray matter volume (schizophrenia interaction)
831 Schizophrenia (age at onset)
832 Lobular breast cancer (menopausal hormone therapy interaction)
833 Breast cancer (menopausal hormone therapy interaction)
834 Psychosis (atypical)
835 Migraine with aura
836 Migraine without aura
837 Serum alkaline phosphatase levels
838 Self-reported allergy
839 Response to platinum-based chemotherapy (carboplatin)
840 Response to platinum-based chemotherapy (cisplatin)
841 Disc degeneration (lumbar)
842 Handedness
843 Sjögren's syndrome
844 Recombination measurement (males)
845 Recombination measurement (females)
846 Gout
847 Serum uric acid levels
848 Social autistic-like traits
849 Barrett's esophagus
850 Esophageal adenocarcinoma
851 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
852 Bronchopulmonary dysplasia
853 Opioid sensitivity
854 Odorant perception (isobutyraldehyde)
855 Cognitive performance
856 Stroke (pediatric)
857 Periodontal microbiota
858 Myasthenia gravis
859 Serum albumin level
860 Amyotrophic lateral sclerosis (age of onset)
861 Protein biomarker
862 HbA2 levels
863 Apolipoprotein Levels
864 Esophageal cancer  (alcohol interaction)
865 Monocyte chemoattractant protein-1
866 Bipolar disorder with mood-incongruent psychosis
867 Response to taxane treatment (placlitaxel)
868 Response to taxane treatment (docetaxel)
869 Serum total protein level
870 Lung Cancer (DNA repair capacity)
871 IgM levels
872 Cholesterol and Triglycerides
873 Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
874 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
875 Cataracts in type 2 diabetes
876 Serum tamsulosin hydrochloride concentration
877 Sagittal craniosynostosis
878 Response to fenofibrate (adiponectin levels)
879 Response to temozolomide
880 Pancreatitis
881 Aspirin exacerbated respiratory disease in asthmatics
882 Chronic obstructive pulmonary disease-related biomarkers
883 Body mass index (interaction)
884 Waist-to-hip circumference ratio (interaction)
885 Spine bone size
886 Methotrexate clearance (acute lymphoblastic leukemia)
887 Aging (facial)
888 Hepatocellular carcinoma in hepatitis B infection
889 Cardiac Troponin-T levels
890 Pulmonary function (interaction)
891 Homeostasis model assessment of beta-cell function (interaction)
892 Homeostasis model assessment of insulin resistance (interaction)
893 Fasting insulin (interaction)
894 Tooth agenesis (third molar)
895 Glycemic traits (pregnancy)
896 Homoarginine levels
897 Metabolite levels (Pyroglutamine)
898 Metabolite levels  (X-11787)
899 Metabolite levels (Dihydroxy docosatrienoic acid)
900 Drug-induced torsades de pointes
901 Periodontitis (DPAL)
902 Periodontitis (CDC/AAP)
903 Periodontitis (PAL4Q3)
904 Periodontitis (Mean PAL)
905 Odorant perception (β-ionone)
906 Behavioural disinhibition (generation interaction)
907 Blood pressure measurement (cold pressor test)
908 Blood pressure measurement (high sodium and potassium intervention)
909 Blood pressure measurement (low sodium intervention)
910 Blood pressure measurement (high sodium intervention)
911 Schizophrenia, schizoaffective disorder or bipolar disorder
912 Amyotrophic lateral sclerosis (sporadic)
913 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
914 Multiple sclerosis or amyotrophic lateral sclerosis
915 Coronary artery disease or ischemic stroke
916 Coronary artery disease or large artery stroke
917 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
918 Schizophrenia or bipolar disorder
919 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
920 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
921 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
922 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
923 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
924 Response to alcohol consumption (flushing response)
925 Alcohol consumption (maxi-drinks)
926 Body mass index (education interaction)
927 Liver enzyme levels (aspartate transaminase)
928 Lung function (FEV1)
929 Lung function (FVC)
930 Lung function (FEV1/FVC)
931 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
932 Relative hand skill
933 Relative hand skill in reading disability
934 Follicule stimulating hormone
935 Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)
936 Thrombin generation potential phenotypes
937 Contrast sensitivity
938 Tooth agenesis (mandibular third molar)
939 Anxiety in major depressive disorder
940 Cognitive decline (age-related)
941 Systolic blood pressure (alcohol consumption interaction)
942 Diastolic blood pressure (alcohol consumption interaction)
943 Mean arterial pressure (alcohol consumption interaction)
944 Pulse pressure (alcohol consumption interaction)
945 Serum dimethylarginine levels (asymmetric/symetric ratio)
946 Symmetrical dimethylarginine levels
947 Asymmetrical dimethylarginine levels
948 Memory performance
949 Bone properties (heel)
950 Bipolar disorder (body mass index interaction)
951 IgG glycosylation
952 Multiple sclerosis (OCB status)
953 Bulimia nervosa
954 Eating disorders (purging via substances)
955 Adverse response to radiation therapy
956 Brain connectivity
957 Congenital heart malformation
958 Post-traumatic stress disorder
959 Response to antidepressant treatment (citalopram)
960 Osteosarcoma
961 Pit-and-Fissure caries
962 Smooth-surface caries
963 Narcolepsy with cataplexy
964 Venous thromboembolism (SNP x SNP interaction)
965 Vitiligo (non-segmental)
966 Alzheimer's disease (cognitive decline)
967 Response to anti-TNF therapy in rheumatoid arthritis
968 Heart rate
969 Temporomandibular joint disorders
970 DNA methylation (variation)
971 DNA methylation (parent-of-origin)
972 Age-related macular degeneration (extreme sampling)
973 Multiple myeloma (IgH translocation)
974 Multiple myeloma (hyperdiploidy)
975 Ovarian cancer in BRCA1 mutation carriers
976 Breast Cancer in BRCA1 mutation carriers
977 B cell non-Hodgkin lymphoma
978 Sexual dimorphism in anthropometric traits
979 Sunburns
980 Retinal arteriolar caliber
981 Non-melanoma skin cancer
982 Paclitaxel-induced neuropathy
983 Anthropometric traits in newborns
984 Migraine - clinic-based
985 Fat distribution (HIV)
986 Aortic-valve calcification
987 Allergic sensitization
988 Cervical cancer
989 Mathematical ability in children with dyslexia
990 Beta-2 microglubulin plasma levels
991 Femoral neck bone geometry and menarche (age at onset)
992 Rhegmatogenous retinal detachment
993 Glycemic traits
994 Sickle cell anemia (haemolysis)
995 Self-employment
996 Addiction
997 Job-related exhaustion
998 Pubertal anthropometrics
999 Esophageal squamous cell cancer (length of survival)
1000 Helicobacter pylori serologic status
1001 Crohn's disease (need for surgery)
1002 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
1003 Oleic acid (18:1n-9) plasma levels
1004 Cystic fibrosis-related diabetes
1005 Coronary arterial lesions in patients with Kawasaki disease
1006 Methamphetamine dependence
1007 Serum selenium levels
1008 Primary tooth development (time to first tooth eruption)
1009 Primary tooth development (number of teeth)
1010 Narcolepsy (age of onset)
1011 Narcolepsy (onset before 2009 H1N1 influenza pandemic)
1012 Asthma (corticosteroid response)
1013 Response to cytidine analogues (gemcitabine)
1014 Response to cytadine analogues (cytosine arabinoside)
1015 Breast cancer (early onset)
1016 Chronic obstructive pulmonary disease (moderate to severe)
1017 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)
1018 Plasma amyloid beta peptide concentrations (ABx-42)
1019 Plasma amyloid beta peptide concentrations (ABx-40)
1020 Response to methotrexate in rheumatoid arthritis
1021 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
1022 Cleft plate (environmental tobacco smoke interaction)
1023 Urinary uromodulin levels
1024 Plasma plasminogen activator levels
1025 Urinary albumin excretion rate in type 1 diabetes
1026 Anterior chamber depth
1027 Plasma homocysteine levels (post-methionine load test)
1028 Lung cancer (smoking interaction)
1029 Smoking quantity
1030 Age of smoking initiation
1031 Clubfoot
1032 Preschool internalizing problems
1033 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
1034 Optic nerve measurement (cup-to-disc ratio)
1035 Serum IgA levels
1036 Chronic mucus hypersecretion
1037 Longevity (90 years and older)
1038 Longevity (85 years and older)
1039 Osteoarthritis (hand, severe)
1040 White matter microstructure (global fractional anisotropy)
1041 Non-small cell lung cancer (recurrence rate)
1042 Serum vitamin D-binding protein levels
1043 Plasma thyroid-stimulating hormone levels
1044 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
1045 Colorectal cancer (diet interaction)
1046 Ejection fraction in Tripanosoma cruzi seropositivity
1047 Antibody status in Tripanosoma cruzi seropositivity
1048 Parasitemia in Tripanosoma cruzi seropositivity
1049 PR interval in Tripanosoma cruzi seropositivity
1050 QRS duration in Tripanosoma cruzi seropositivity
1051 QT interval in Tripanosoma cruzi seropositivity
1052 Autoimmune hepatitis type-1
1053 Fractional exhaled nitric oxide (childhood)
1054 Plasma cystastin c levels in acute coronary syndrome
1055 Hippocampal sclerosis of aging
1056 Glomerular filtration rate
1057 Asthma and hay fever
1058 Musician's dystonia
1059 Glaucoma (primary angle closure)
1060 Vaspin levels
1061 Comprehensive strength and appendicular lean mass
1062 Androgen levels
1063 Epilepsy (generalized)
1064 Esophageal cancer (squamous cell)
1065 Drug-induced liver injury
1066 Mean corpuscular hemoglobin concentration
1067 Red blood cell count
1068 Plasminogen activator inhibitor type 1 levels (PAI-1)
1069 Type 1 diabetes nephropathy
1070 Response to amphetamines
1071 Breast cancer (male)
1072 Complement C3 and C4 levels
1073 Periodontal disease-related phenotypes
1074 Anxiety and major depressive disorder
1075 Conotruncal heart defects
1076 Staphylococcus aureus infection
1077 Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
1078 Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
1079 Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
1080 Anger
1081 Pulmonary emphysema
1082 Puberty onset (genital enlargement)
1083 Puberty onset
1084 Puberty onset (breast development)
1085 Recombination measurement
1086 Thyroid peroxidase antibody levels
1087 Type 2 diabetes (young onset) and obesity
1088 Chronic obstructive pulmonary disease (severe)
1089 Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)
1090 Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)
1091 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
1092 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
1093 Rheumatoid arthritis (ACPA-negative)
1094 Urinary metabolites (H-NMR features)
1095 Political ideology
1096 Parent of origin effect on language impairment (paternal)
1097 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
1098 Intracerebral hemorrhage
1099 Serum metabolite levels
1100 Smoking initiation
1101 Serum thyroid-stimulating hormone levels
1102 Bladder cancer (smoking interaction)
1103 Response to methotrexate in juvenile idiopathic arthritis
1104 Leishmaniasis (visceral)
1105 Tumor biomarkers
1106 White matter integrity (interaction)
1107 LDL (oxidized)
1108 Bipolar disorder (mania)
1109 Monocyte count
1110 Hepatitis C induced liver cirrhosis
1111 Breast cancer (prognosis)
1112 Lymphoma
1113 Squamous cell carcinoma
1114 β2-Glycoprotein I (β2-GPI) plasma levels
1115 End-stage coagulation
1116 Schizophrenia (negative symptoms)
1117 Beta-trace protein levels
1118 Paraoxonase activity
1119 Type 2 diabetes (dietary heme iron intake interaction)
1120 Serum ceruloplasmin levels
1121 Metabolite levels (HVA)
1122 Metabolite levels (5-HIAA)
1123 Metabolite levels (MHPG)
1124 Metabolite levels (5-HIAA/ MHPG Ratio)
1125 Metabolite levels (HVA/5-HIAA ratio)
1126 Metabolite levels (HVA/MHPG ratio)
1127 Metabolite levels (HVA-5-HIAA Factor score)
1128 Urinary symptoms in response to radiotherapy in prostate cancer
1129 Vascular dementia
1130 Circulating vasoactive peptide levels
1131 Schizophrenia (cytomegalovirus infection interaction)
1132 Response to cholinesterase inhibitors in Alzheimer's disease
1133 Tetralogy of Fallot
1134 Epstein-Barr virus immune response (EBNA-1)
1135 Renal transplant outcome
1136 Presence of antiphospholipid antibodies
1137 Iron deficiency
1138 Intelligence (childhood)
1139 Orofacial clefts (interaction)
1140 QT interval (interaction)
1141 Response to dabigatran etexilate treatment
1142 Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
1143 Pulmonary arterial hypertension (without BMPR2 mutations)
1144 Aspirin hydrolysis (plasma)
1145 Estradiol plasma levels (breast cancer)
1146 Retinopathy in non-diabetics
1147 Thiazide-induced adverse metabolic effects in hypertensive patients
1148 Non-alcoholic fatty liver disease
1149 Thyroid hormone levels
1150 Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)
1151 AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
1152 Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
1153 Palmitic acid (16:0) plasma levels
1154 Sex hormone levels
1155 Pediatric autoimmune diseases
1156 Atopic march
1157 Influenza A (H1N1) infection
1158 Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
1159 Palmitoleic acid (16:1n-7) plasma levels
1160 Forced expiratory volume in 1 second (environmental interaction)
1161 Parkinson's disease (age of onset)
1162 Cadmium levels
1163 Aluminium levels
1164 Inguinal hernia
1165 Influenza A (H1N1) severity
1166 Antipsychotic drug-induced weight gain (time interaction)
1167 Length of menstrual cycle
1168 Major depressive disorder (stressful life events interaction)
1169 Ischemic stroke
1170 Cannabis use (age at onset)
1171 Lapatinib-induced hepatotoxicity
1172 Cobalt levels
1173 Chromium levels
1174 Copper levels
1175 Mercury levels
1176 Manganese levels
1177 Molybdenum levels
1178 Nickel levels
1179 Lead levels
1180 Zinc levels
1181 Thoracic-to-hip circumference ratio
1182 Calcaneal bone ultrasound measurement (speed of sound)
1183 IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7)
1184 Rapid functional decline in sporadic amyotrophic lateral sclerosis
1185 Systolic blood pressure (cigarette smoking interaction)
1186 Low bone mineral density (hip)
1187 Low bone mineral density (spine)
1188 Urinary albumin-to-creatinine ratio in diabetes
1189 Bipolar disorder and eating disorder
1190 Eating disorder in bipolar disorder
1191 Non-cardia gastric cancer
1192 C-reactive protein levels in ischemic stroke
1193 Fibrinogen levels in ischemic stroke
1194 Cerebrospinal fluid clusterin levels
1195 LDL cholesterol levels
1196 Thrombomodulin levels in ischemic stroke
1197 Creatinine levels in ischemic stroke
1198 Thrombin-antithrombin complex levels in ischemic stroke
1199 Prothrombin fragments F1+2 levels in ischemic stroke
1200 Cardiovascular disease in hypertension (ACE inhibitor interaction)
1201 Multiple myeloma and monoclonal gammopathy
1202 Response to lithium treatment in bipolar disorder
1203 Stearic acid (18:0) plasma levels
1204 Non-glioblastoma glioma
1205 circulating leptin levels
1206 circulating leptin levels adjusted for BMI
1207 Hair morphology
1208 Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
1209 Rheumatoid factor seropositivity in rheumatoid arthritis
1210 Basal metabolic rate
1211 Gut microbiome composition (summer and winter)
1212 Entorhinal cortical volume
1213 Entorhinal cortical thickness
1214 Whole-brain volume
1215 Entorhinal cortical thickness (Alzheimer's disease interaction)
1216 Total ventricular volume
1217 Entorhinal cortical volume (Alzheimer's disease interaction)
1218 Total ventricular volume (Alzheimer's disease interaction)
1219 Whole-brain volume (Alzheimer's disease interaction)
1220 antipsychotic drug dosage in schizophrenia or schizoaffective disorder
1221 Bipolar disorder or major depressive disorder (combined)
1222 Obstructive sleep apnea
1223 World class endurance athleticism
1224 Body mass index variance
1225 Factor VIII levels
1226 vWF levels
1227 Factor VII levels
1228 Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
1229 Spontaneous preterm birth (preterm delivery)
1230 Spontaneous preterm birth (preterm birth)
1231 Electrodermal activity
1232 B-type natriuretic peptide
1233 Shingles
1234 Schizophrenia (inflammation and infection response interaction)
1235 Interferon alpha levels in systemic lupus erythematosus
1236 Superior frontal gyrus grey matter volume
1237 Mammographic density (dense area)
1238 Mammographic density (non-dense area)
1239 Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
1240 Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
1241 Myocardial infarction in coronary artery disease
1242 Congenital left-sided heart lesions (maternal effect)
1243 Body mass index (change over time)
1244 Underweight status
1245 Overweight status
1246 Reading or mathematical ability
1247 Toenail selenium levels
1248 Blood and toenail selenium levels
1249 Cerebrospinal fluid levels of Alzheimer's disease-related proteins
1250 Maximal oxygen uptake response
1251 Male fertility
1252 Fasting plasma glucose (childhood)
1253 Expressive vocabulary in infants
1254 Mitochondrial DNA levels
1255 Diabetic retinopathy in type 2 diabetes
1256 Age-related cataracts (age at onset)
1257 Age-related cataracts
1258 Hyperopia
1259 Myopia
1260 Coffee consumption (cups per day)
1261 Alzheimer's disease (age of onset)
1262 Alloimmunization response to red blood cell transfusion in sickle cell anemia
1263 Smoking cessation in chronic obstructive pulmonary disease
1264 Enteric fever
1265 Episodic memory
1266 Psychosis and Alzheimer's disease
1267 Psychosis in Alzheimer's disease
1268 Lifetime average cigarettes per day in chronic obstructive pulmonary disease
1269 Current cigarettes per day in chronic obstructive pulmonary disease
1270 Fractional exhaled nitric oxide levels
1271 Hashimoto thyroiditis versus Graves' disease
1272 Iron status biomarkers (ferritin levels)
1273 Iron status biomarkers (transferrin saturation)
1274 Iron status biomarkers (transferrin levels)
1275 Iron status biomarkers (iron levels)
1276 Refractive astigmatism
1277 Anti-saccade response
1278 Inflammatory biomarkers in Kawasaki disease
1279 Suicide in bipolar disorder
1280 Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)
1281 Acoustic startle blink response
1282 Acute lymphoblastic leukemia (adolescents and young adults)
1283 Pulmonary artery enlargement in chronic obstructive pulmonary disease
1284 Pulmonary artery enlargement and chronic obstructive pulmonary disease
1285 Chronic bronchitis in chronic obstructive pulmonary disease
1286 Breastfeeding duration
1287 Chronic bronchitis and chronic obstructive pulmonary disease
1288 Seasonality
1289 Kidney function decline traits
1290 Cervical artery dissection
1291 Urgency urinary incontinence
1292 Kashin-Beck disease
1293 Sepsis from pneumonia (survival)
1294 Bilirubin levels in extreme obesity
1295 Gastritis
1296 Nicotine glucouronidation
1297 Cotinine glucuronidation
1298 Yang-deficiency constitution
1299 Hepatitis
1300 Emphysema imaging phenotypes
1301 Airway imaging phenotypes
1302 NT-proBNP levels in acute coronary syndrome
1303 Low high density lipoprotein cholesterol levels
1304 Obsessive-compulsive symptoms
1305 Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
1306 Sex ratio
1307 Early response to risperidone in schizophrenia
1308 Methotrexate phramacokinetics (acute lymphoblastic leukemia)
1309 Serum lycopene concentrations
1310 Perioperative myocardial infarction in coronary artery bypass surgery
1311 Platelet thrombus formation
1312 Incident myocardial infarction
1313 Incident coronary heart disease
1314 Rotator cuff tears
1315 Hemoglobin levels
1316 Ischemic stroke (cardioembolic)
1317 Ischemic stroke (large artery atherosclerosis)
1318 Ischemic stroke (small artery occlusion)
1319 Ischemic stroke (undetermined subtype)
1320 Pediatric areal bone mineral density (radius)
1321 Pediatric bone mineral content (radius)
1322 Betaine levels in individuals undergoing cardiac evaluation
1323 Alzheimer's disease or small vessel stroke
1324 Response to interferon beta in multiple sclerosis
1325 Attention function in attention deficit hyperactive disorder
1326 Chronotype
1327 Morning vs. evening chronotype
1328 Response to montelukast in asthma (change in FEV1)
1329 Suicide attempts in major depressive disorder
1330 Suicide ideation score in major depressive disorder
1331 Suicide
1332 Postprandial triglyceride response to high fat diet meal
1333 Blond vs non-blond hair color
1334 Brown vs. non-brown hair color
1335 Light vs. dark hair color
1336 Black vs. non-black hair color
1337 Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
1338 Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
1339 Cutaneous malignant melanoma
1340 Longitudinal change in brain amyloid plaque burden
1341 Glomerular filtration rate (cystatin C)
1342 Cardia gastric cancer
1343 Glycerophospholipid levels
1344 Amino acid levels
1345 Acylcarnitine levels
1346 Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
1347 Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
1348 Longitudinal alcohol consumption
1349 Yu-Zhi constitution type in type 2 diabetes
1350 Soluble interleukin-2 receptor subunit alpha
1351 Autism spectrum disorder
1352 Percentage gas trapping
1353 Dysphagia
1354 Nicotine metabolite ratio
1355 Erythrocyte cadmium concentration
1356 Erythrocyte cadmium concentration in never smokers
1357 Cerebrospinal fluid clusterin levels in APOEe4+ carriers
1358 Cerebrospinal fluid clusterin levels in APOEe4- carriers
1359 Aggressiveness in attention deficit hyperactivity disorder
1360 Plasma clusterin levels
1361 Mitral valve prolapse
1362 Skin colour saturation
1363 LDL peak particle diameter (total fat intake interaction)
1364 Glomerular filtration rate (creatinine)
1365 S-phenylmercapturic acid levels in smokers
1366 Thionamide-induced agranulocytosis in Graves' disease
1367 Ideal cardiovascular health (clinical)
1368 Adiponectin levels (BMI-adjusted)
1369 Gut microbiome composition (winter)
1370 Plasma lactate levels
1371 Verbal-numerical reasoning
1372 Response to zileuton treatment in asthma (FEV1 change interaction)
1373 Anthracycline-induced cardiotoxicity in childhood cancer
1374 Severe malaria
1375 Exploratory eye movement dysfunction in schizophrenia (cognitive search score)
1376 Discordance in emotional problems in monozygotic twins
1377 Cerebrospinal fluid p-Tau181p:AB1-42 ratio
1378 Cerebrospinal fluid t-tau:AB1-42 ratio
1379 Survival in colorectal cancer
1380 Survival in colorectal cancer (non-distant metastatic)
1381 Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)
1382 Exploratory eye movement dysfunction in schizophrenia (responsive search score)
1383 Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)
1384 Cerebral amyloid deposition positivity (PET imaging)
1385 Bronchial hyperresponsiveness in asthma
1386 Lipoprotein (a) levels
1387 Glomerular filtration rate in chronic kidney disease
1388 Proteinuria in chronic kidney disease
1389 Proteinuria and chronic kidney disease
1390 Diabetic kidney disease
1391 Coagulation factor levels
1392 Nodular sclerosis Hodgkin lymphoma
1393 Prostate cancer (survival)
1394 Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
1395 Delta-5 desaturase activity
1396 Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
1397 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
1398 Delta-6 desaturase activity
1399 Bone mineral density (spine) and age at menarche
1400 Bone mineral density (hip) and age at menarche
1401 Age-related hearing impairment (interaction)
1402 Cannabis use
1403 Prostate cancer (gene x gene interaction)
1404 Glucocorticoid-induced osteonecrosis (time dependent analysis)
1405 Cognitive decline rate in late mild cognitive impairment
1406 Cerebral amyloid deposition (PET imaging)
1407 Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)
1408 Trans fatty acid levels
1409 Clozapine-induced cytotoxicity
1410 Parkinson disease and lewy body pathology
1411 Total bilirubin levels in HIV-1 infection
1412 Neutrophil count in HIV-infection
1413 HDL Cholesterol in HIV-infection
1414 Hand grip strength
1415 Alzheimer's disease (survival time)
1416 Exfoliation syndrome
1417 Crohn's disease-related phenotypes
1418 Verbal declarative memory
1419 Endothelial growth factor levels
1420 Airway wall thickness
1421 Airway responsiveness in chronic obstructive pulmonary disease
1422 Glucose homeostasis traits
1423 Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
1424 Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
1425 Red wine liking
1426 White wine liking
1427 Antibody level in response to infection
1428 Nonsyndromic cleft lip with or without cleft palate
1429 Colorectal cancer (aspirin and/or NSAID use interaction)
1430 Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
1431 Peanut allergy
1432 Response to Dalcetrapib treatment in acute coronary syndrome
1433 Lipoprotein (a) - cholesterol levels
1434 Platinum-induced myelosuppression in non-small cell lung cancer
1435 Immunoglobulin G index levels in multiple sclerosis
1436 Oligoclonal band status in multiple sclerosis
1437 Subcortical brain region volumes
1438 Optic cup area
1439 Exudative age-related macular degeneration
1440 Salivary gland carcinoma
1441 Disease-free survival in breast cancer
1442 Developmental dysplasia of the hip
1443 Sasang constitutional medicine type (So-Eum)
1444 Carotid artery intima media thickness (sex interaction)
1445 Gene methylation in lung tissue
1446 Facial pigmentation
1447 ADAMTS13 activity
1448 Alzheimer's disease (APOE e4 interaction)
1449 Survival in rectal cancer
1450 Survival in colon cancer
1451 Survival in microsatellite instability low/stable colorectal cancer
1452 Creutzfeldt-Jakob disease (sporadic)
1453 Classic bladder exstrophy
1454 Psychotic symptoms and prion disease
1455 Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
1456 Mood disorder and prion disease
1457 Behavioral disturbance or psychiatric symptoms and prion disease
1458 Psychotic symptoms in prion disease
1459 Mood disorder in prion disease
1460 Behavioral disturbance or psychiatric symptoms in prion disease
1461 Response to serotonin reuptake inhibitors in major depressive disorder
1462 Recalcitrant atopic dermatitis
1463 Cytokine-stimulated IL-6 production
1464 Perceived skin darkness
1465 Survival in endocrine treated breast cancer (estrogen-receptor positive)
1466 Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
1467 Prostate cancer aggressiveness
1468 Paclitaxel-induced cytotoxicity
1469 Type 1 diabetes and autoimmune thyroid diseases
1470 Obesity in adult survivors of childhood cancer exposed to cranial radiation
1471 Obesity in adult survivors of childhood cancer not exposed to cranial radiation
1472 Sporadic pituitary adenoma
1473 Urate levels in lean individuals
1474 Urate levels (BMI interaction)
1475 Urate levels in obese individuals
1476 Urate levels in overweight individuals
1477 Peak creatinine levels in vancomycin therapy
1478 Mucinous ovarian carcinoma
1479 Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
1480 Corticobasal degeneration
1481 Number of children
1482 Number of pregnancies
1483 Number of children (6+ vs. 0 or 1)
1484 Inflammatory skin disease
1485 Lifespan
1486 Suicide behavior
1487 Advanced glycation end-product levels
1488 Postoperative atrial fibrillation in coronary artery bypass grafting surgery
1489 Serum alpha1-antitrypsin levels
1490 Acute kidney injury in coronary artery bypass surgery (creatinine rise)
1491 Bone mineral accretion in asthma (oral corticosteroid dose interaction)
1492 Hypersomnia during a major depressive episode in bipolar disorder
1493 Noise-induced hearing loss
1494 Cutaneous lupus erythematosus
1495 Metastasis at diagnosis in osteosarcoma
1496 Cough in response to angiotensin-converting enzyme inhibitor drugs
1497 Milk allergy
1498 Food allergy
1499 Egg allergy
1500 MGMT methylation in smokers
1501 Body mass index (age interaction)
1502 Lead levels in blood
1503 Polychlorinated biphenyl levels
1504 Vein graft stenosis in coronary artery bypass grafting
1505 Left superior temporal gyrus thickness (schizophrenia interaction)
1506 Atrioventricular septal defects in Down syndrome
1507 Multiple myeloma (survival)
1508 Progression free survival in metastatic colorectal cancer (treatment interaction)
1509 Bipolar disorder (inflammation and infection response interaction)
1510 Depressive episodes in bipolar disorder
1511 Depressive and manic episodes in bipolar disorder
1512 Alzheimer's disease in APOE e4- carriers
1513 Alzheimer's disease in APOE e4+ carriers
1514 Juvenile osteochondritis dissecans
1515 Waist-to-hip ratio adjusted for body mass index
1516 Postburn hypertrophic scarring severity
1517 White matter lesion progression
1518 Cytokine and corticosteroid-stimulated IL-6 production
1519 Plasma homocysteine levels
1520 Coronary artery aneurysm in Kawasaki disease
1521 Sitting height ratio
1522 Diisocyanate-induced asthma
1523 Trichloroethylene-induced hypersensitivity syndrome
1524 Cingulate cortical amyloid beta load
1525 Susceptibility to persistent hepatitis B virus infection
1526 Staphylococcus aureus nasal carriage (persistent)
1527 Staphylococcus aureus nasal carriage (intermittent)
1528 Ear protrusion
1529 Lobe size
1530 Lobe attachment
1531 Antitragus size
1532 Helix rolling
1533 Folding of antihelix
1534 Superior crus of antihelix expression
1535 Ear morphology
1536 Tragus size
1537 Gait variability
1538 Gait rhythm
1539 Tandem gait
1540 Childhood and early adolescence aggressive behavior
1541 Middle childhood and early adolescence aggressive behavior
1542 Early childhood aggressive behavior
1543 Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
1544 Epilepsy and lamotrigine-induced maculopapular eruptions
1545 Manic episodes in bipolar disorder
1546 Skin fluorescence in type 1 diabetes
1547 3-hydroxypropylmercapturic acid levels in smokers
1548 Triptolide cytotoxicity
1549 Gastric adenocarcinoma (histologically verified)
1550 3-hydroxy-1-methylpropylmercapturic acid levels in smokers
1551 Systemic lupus erythematosus or rheumatoid arthritis
1552 Joint damage progression in ACPA-negative rheumatoid arthritis
1553 Sight-threatening diabetic retinopathy in type 2 diabetes
1554 Severe influenza A (H1N1) infection
1555 Membranous nephropathy
1556 Glucocorticoid-induced osteonecrosis
1557 Glucocorticoid-induced osteonecrosis (age 10 years and older)
1558 L-arginine levels
1559 Exhaled carbon monoxide levels
1560 Colorectal cancer (calcium intake interaction)
1561 Clozapine-induced agranulocytosis
1562 Mammographic density
1563 Electroencephalogram traits
1564 Febrile seizures
1565 Febrile seizures (MMR vaccine-related)
1566 Febrile seizures (MMR vaccine-unrelated)
1567 Circulating phylloquinone levels
1568 General cognitive ability
1569 Serum VEGFR2 concentration
1570 Infant length
1571 Fetal hemoglobin levels in sickle cell anemia
1572 Anxiety disorder
1573 Very long-chain saturated fatty acid levels (fatty acid 20:0)
1574 Very long-chain saturated fatty acid levels (fatty acid 22:0)
1575 Very long-chain saturated fatty acid levels (fatty acid 24:0)
1576 Vascular brain injury
1577 Hippocampal sclerosis
1578 Cerebral amyloid angiopathy
1579 Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)
1580 Bronchodilator response in asthma
1581 Marginal zone lymphoma
1582 Erythema nodosum in inflammatory bowel disease
1583 Pyoderma gangrenosum in inflammatory bowel disease
1584 Response to simvastatin treatment (PCSK9 protein level change)
1585 Diabetic nephropathy in type 1 diabetes
1586 Response to Homoharringtonine (cytotoxicity)
1587 Red blood cell fatty acid levels
1588 Lewy body disease
1589 Neuritic plaque
1590 Neurofibrillary tangles
1591 Dementia and core Alzheimer's disease neuropathologic changes
1592 Depressive symptoms (SSRI exposure interaction)
1593 Response to inhaled glucocorticoid treatment in asthma (change in FEV1)
1594 Motion sickness
1595 Cold medicine related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS-TEN) with severe mucosal involvement
1596 Serum IgE levels
1597 Plasma renin activity levels
1598 Mean arterial pressure
1599 Mild influenza (H1N1) infection
1600 Pulse pressure
1601 Myositis
1602 Severity of facial solar lentigines
1603 White matter hyperintensities in ischemic stroke
1604 Subjective response to lithium treatment
1605 Subjective response to lithium treatment in bipolar disorder
1606 Objective response to lithium treatment
1607 Objective response to lithium treatment in bipolar disorder
1608 Response to radiotherapy in prostate cancer (toxicity, urinary frequency)
1609 Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)
1610 Lung disease severity in cystic fibrosis
1611 Low vWF levels
1612 White matter lesion progression (adjusted for white matter lesion burden at baseline)
1613 Cirrhosis (alcohol related)
1614 Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)
1615 Skin and soft tissue Staphylococcus aureus infection
1616 EGFR mutation-positive lung adenocarcinoma
1617 Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
1618 Visceral adipose tissue
1619 Cardiovascular disease in hypertension (calcium channel blocker interaction)
1620 Myocardial infarction in hypertension (calcium channel blocker interaction)
1621 Sense of smell
1622 Childhood body mass index
1623 Setpoint viral load in HIV-1 infection
1624 Response to exercise (triglyceride levels)
1625 Response to thiopurine in inflammatory bowel disease (leukopenia)
1626 Response to Pazopanib in cancer (hepatotoxicity)
1627 Adenocarcinoma
1628 Pelvic organ prolapse
1629 Pelvic organ prolapse (moderate/severe)
1630 Fibrinogen levels
1631 Colorectal or endometrial cancer
1632 Advanced age-related macular degeneration
1633 Gut microbiome composition (summer)
1634 Post bronchodilator FEV1 in COPD
1635 Survival in colorectal cancer (distant metastatic)
1636 Post bronchodilator FEV1
1637 Post bronchodilator FEV1/FVC ratio in COPD
1638 Microalbuminuria
1639 Urinary albumin-to-creatinine ratio in non-diabetics
1640 Response to carboplatin in ovarian cancer (MTT IC50)
1641 Pre bronchodilator FEV1
1642 Pre bronchodilator FEV1/FVC ratio
1643 Urinary albumin-to-creatinine ratio
1644 Post bronchodilator FEV1/FVC ratio
1645 Late-onset myasthenia gravis
1646 Psoriasis vulgaris
1647 Cutaneous psoriasis
1648 Response to statins (HDL cholesterol change)
1649 Anxiety disorder (factor score)
1650 Triglyceride levels
1651 HDL cholesterol levels
1652 IgG1 response to Plasmodium falciparum antigen (GLURP)
1653 Ideal cardiovascular health (clinical and behavioural)
1654 Body fat percentage
1655 Alzheimer disease and age of onset
1656 Sleep latency
1657 Small vessel stroke
1658 Waist circumference adjusted for body mass index
1659 Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
1660 Epstein Barr virus nuclear antigen 1 IgG levels
1661 Glaucoma (low intraocular pressure)
1662 Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)
1663 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)
1664 Response to paclitaxel in ovarian cancer (MTT IC50)
1665 Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)
1666 Glomerular filtration rate in diabetics (creatinine)
1667 Mosaic loss of chromosome Y
1668 Thrombosis
1669 Bone mineral density (femoral neck)
1670 Developmental language disorder
1671 Developmental language disorder (linguistic errors)
1672 Developmental language disorder (syntactic complexity)
1673 Parental longevity (mother's age at death)
1674 Parental extreme longevity (95 years and older)
1675 Coenzyme Q10 levels
1676 Parental longevity (combined parental age at death)
1677 Glomerular filtration rate in non diabetics (creatinine)
1678 Scalp hair shape
1679 Beard thickness
1680 Eyebrow thickness
1681 Monobrow thickness
1682 Hair greying
1683 Balding
1684 Survival in head and neck cancer
1685 Response to cognitive-behavioural therapy in anxiety disorder
1686 Apolipoprotein A-IV levels
1687 Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
1688 Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
1689 Spherical equivalent (joint main effects and education interaction)
1690 Posterior cortical atrophy and Alzheimer's disease
1691 Drug abuse
1692 Endometrial endometrioid carcinoma
1693 Response to fenofibrate (HDL cholesterol levels)
1694 Response to fenofibrate (LDL cholesterol levels)
1695 Response to fenofibrate (total cholesterol levels)
1696 Response to fenofibrate (triglyceride levels)
1697 Food addiction
1698 Clinical laboratory measurements
1699 Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
1700 Daytime sleep phenotypes
1701 Night sleep phenotypes
1702 Large artery stroke
1703 Antithyroid drug-induced agranulocytosis
1704 Anti-thyroid drug induced agranulocytosis
1705 Non-chemotherapy drug induced agranulocytosis
1706 Alcohol dependence symptom count
1707 Opioid dependence
1708 Cancer
1709 Cancer (pleiotropy)
1710 Liver fibrosis severity in HIV/hepatitis C co-infection
1711 Parkinson's disease (pesticide exposure interaction)
1712 Response to radiotherapy in prostate cancer (overall toxicity)
1713 Liver disease severity in Alagille syndrome
1714 Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
1715 Bone mineral density (total hip)

In [7]:

    

def get_diseaseId(disease_name):
    cur = myConnection.cursor()

    cur.execute( """select * from enfermedad where nombre = "%s" """ % (disease_name) )
    
    id_enf = None
    for id_, nombre_enf in cur.fetchall() :
        id_enf = id_
        
    if not id_enf:
        cur.execute("""insert into enfermedad values (NULL, "%s" )""" % (disease_name))
        cur.execute("SELECT LAST_INSERT_ID()")
        
        
        
        id_enf = cur.fetchall()[0][0]
        
        myConnection.commit()
        
    return id_enf


    

In [47]:

    

def get_platId(plat_name):
    cur = myConnection.cursor()

    cur.execute( """select * from plataforma where nombre = "%s" """ % (plat_name) )
    
    id_plat = None
    for id_, nombre_plat in cur.fetchall() :
        id_plat = id_
        
    if not id_plat:
        print("""insert into plataforma values (NULL, "%s" )""" % (plat_name))
        cur.execute("""insert into plataforma values (NULL, "%s" )""" % (plat_name))
        cur.execute("SELECT LAST_INSERT_ID()")
        
                
        id_plat = cur.fetchall()[0][0]
        
        myConnection.commit()
        
    return id_plat

for index, row in df.iterrows():
    plat_name = row['PLATFORM [SNPS PASSING QC]']
    plat_id = get_platId(plat_name)


    

    




---------------------------------------------------------------------------
OperationalError                          Traceback (most recent call last)
<ipython-input-47-7fa23b42eb96> in <module>()
     22 for index, row in df.iterrows():
     23     plat_name = row['PLATFORM [SNPS PASSING QC]']
---> 24     plat_id = get_platId(plat_name)

<ipython-input-47-7fa23b42eb96> in get_platId(plat_name)
      1 def get_platId(plat_name):
----> 2     cur = myConnection.cursor()
      3 
      4     cur.execute( """select * from plataforma where nombre = "%s" """ % (plat_name) )
      5 

C:\Users\Alex\Anaconda3\lib\site-packages\mysql\connector\connection.py in cursor(self, buffered, raw, prepared, cursor_class, dictionary, named_tuple)
   1381             raise errors.InternalError("Unread result found.")
   1382         if not self.is_connected():
-> 1383             raise errors.OperationalError("MySQL Connection not available.")
   1384         if cursor_class is not None:
   1385             if not issubclass(cursor_class, CursorBase):

OperationalError: MySQL Connection not available.

In [8]:

    

def get_lociId(loci_name):
    cur = myConnection.cursor()

    cur.execute( """select * from loci where nombre = "%s" """ % (disease_name) )
    
    id_loci = None
    for id_, nombre_enf in cur.fetchall() :
        id_loci = id_
        
    if not id_loci:
        print("""insert into enfermedad values (NULL, "%s", )""" % (disease_name))
        cur.execute("""insert into enfermedad values (NULL, "%s" )""" % (disease_name))
        cur.execute("SELECT LAST_INSERT_ID()")
        
        
        
        id_enf = cur.fetchall()[0][0]
        
        myConnection.commit()
        
    return id_enf


    

In [9]:

    

hostname = '127.0.0.1'
username = 'alexacl95'
password = 'SUSAna05'
database = 'programacion'

myConnection = mysql.connector.connect( host=hostname, user=username, passwd=password, db=database )

for index, row in df.iterrows():
    dis_name = row['DISEASE/TRAIT']
    dissease_id = get_diseaseId(dis_name)


print()

myConnection.close()


    

In [ ]:

    

http://pandas.pydata.org/pandas-docs/stable/generated/pandas.read_sql_query.html


    

In [ ]: